Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Operating Margin (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Operating Margin for 9 consecutive years, with 1214.7% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 165536.0% to 1214.7% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.83% through Dec 2025, up 39364.0% year-over-year, with the annual reading at 39.17% for FY2025, 34516.0% up from the prior year.
  • Operating Margin hit 1214.7% in Q4 2025 for Sutro Biopharma, up from 499.94% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 1214.7% in Q4 2025 to a low of 1202.0% in Q1 2025.
  • Historically, Operating Margin has averaged 286.28% across 5 years, with a median of 331.06% in 2021.
  • Biggest YoY gain for Operating Margin was 165536bps in 2025; the steepest drop was -76695bps in 2025.
  • Year by year, Operating Margin stood at 328.85% in 2021, then plummeted by -73bps to 570.23% in 2022, then skyrocketed by 107bps to 37.95% in 2023, then plummeted by -1261bps to 440.66% in 2024, then surged by 376bps to 1214.7% in 2025.
  • Business Quant data shows Operating Margin for STRO at 1214.7% in Q4 2025, 499.94% in Q3 2025, and 5.25% in Q2 2025.